We have approached the role of the C4 defects, or C4 'null' alleles, in LE by determining HLA and C4 allotypes and the molecular basis of C4 null phenotypes in two subgroups of LE, namely in subacute cutaneous LE (SCLE) and in systemic LE (SLE).
Genetic studies' 2 of patients with lupus erythematosus (LE), an autoimmune disease, have shown that certain histocompatibility complex (MHC) markers predispose to LE, especially HLA-DR3 and a haplotype HLA-B8, DR3, as well as defects in the early components of the classical complement pathway, Cl, C2, and C4. 3 We have approached the role of the C4 defects, or C4 'null' alleles, in LE by determining HLA and C4 allotypes and the molecular basis of C4 null phenotypes in two subgroups of LE, namely in subacute cutaneous LE (SCLE) and in systemic LE (SLE).
The study groups represent the two extremes of the clinical spectrum of LE. The characteristics of SCLE2 are skin manifestations, photosensitivity, and a good prognosis, whereas patients with SLE' 2 have more severe renal or central nervous system involvement or both with a poor prognosis. After cloning the C4 genes4 5 a more detailed analysis of the C4 genes and defects was possible. The C4 gene region is located in the MHC between the HLA-B and HLA class II genes. It includes the duplicated C4 genes (C4A and C4B) and steroid 21-hydroxylase Received for publication 18 July 1987. Revised version accepted for publication 13 November 1987.
(21-OHA and 21-OHB) genes.5 There is evidence-8 that the number of C4 genes per chromosome may vary; certain C4 null phenotypes result from a gene deletion, whereas some chromosomes express three C4 products. Particularly, the C4A null phenotype in HLA-B8, DR3 haplotype is the result of a large deletion covering the C4A and 21-OHA genes. The presence of this deletion in the haplotype associated with LE and many other autoimmune diseases prompted us to study the C4 gene region in LE in more detail using the Southern blotting technique.
Subjects and methods

PATIENTS
The first group included 11 patients (10 women, one man) with subacute cutaneous LE.9 Duration of the disease varied from three to 37 years (mean 14-9 years). All the patients had pronounced photosensitivity and skin changes as the main manifestation. The clinical picture corresponded to that described before9 and the patients fulfilled no more than four of the ARA criteria for SLE. The second group included 12 patients (11 women, one man) with severe systemic LE. Duration of the disease varied from two to 21 years (mean 9-7 years). All (Promega, Madison, WI) . The digested DNA samples were size separated by 0-8% agarose gel electrophoresis, denatured, and blotted on Hybond-N nylon filters.8 Prehybridisation and hybridisation (48 hours at 42°C) were in 50% formamide, 6xSSC, SxDenhardt's, 0.1% SDS, 50 mmol/l phosphate buffer, and 0-1 mg/ml denatured herring DNA. Filters were washed first in 2 x SSC at room temperature and then twice in 0*3xSSC at 42°C. Restriction enzyme fragments were visualised by autoradiography. A full length C4 specific cDNA probe pA\T-A," and a 21-OH specific probe p21-K4, 16 were used. The pAT-A probe was labelled by nick translation (Amersham) and a 0-9 kb BglI fragment of p21-K4 was labelled by multiprime DNA labelling (Amersham). The probes were kindly provided by Dr Michael C Carroll, Harvard University, Boston.
INTERPRETATION OF SOUTHERN BLOTS
Enzymes TaqI and KpnI produce restriction enzyme fragments which have been shown5 6 16 17 to be, with certain exceptions,6 18 diagnostic for C4A (7.0 kb TaqI, 12-0 kb KpnI), C4B (6.4, 6-0, 5.4 Table 1 shows the frequencies of HLA-B8, DR2, and C4 null alleles in the two patient groups (SCLE and SLE), in the controls, and in the Finnish reference population. The comparison showed that in both patient groups the frequencies of HLA-B8 and DR3 were about twice those in the controls and the reference population. Furthermore, the frequency of C4AO (60% in SCLE and 54% in SLE group), but not C4BO, was clearly higher among the patients than among the controls (22%, p<005). The increased frequency of HLA-DR2 (64% v 33% in SLE, NS, and 25% in the controls, p<0 05) The frequencies of the patients and controls with the gene deletions are summarised in table 1. The two patient groups, SCLE and SLE, did not differ from each other and were combined for statistical purposes. As expected from the C4 phenotypes, the frequency of the C4A/21-OHA deletion (10/23, 43%) in the patients was higher than in the controls (22%, NS). Interestingly, although the frequency of the phenotypic C4BO between the patients and the controls did not deviate (43% v 43%), the frequency of the C4B/21-OHA deletions among the patients (22%) was more than twice that of the controls (9%). The difference was, however, not statistically significant. Of the phenotypic C4A nulls, 83% of the patients and 100% of the controls involved deletions, and the proportions for the C4B nulls were 55% and 20%, respectively.
Discussion
It is established that defects in the complement C4 genes can predispose to LE,' 3 and our present study in Finnish patients confirmed this: 90% of the patients carried at least one C4 null. Furthermore, we confirmed the high frequency of HLA-B8 and DR3 in both subgroups of LE. The comparison between the two groups, SCLE and SLE, showed that they had similar MHC patterns except that 
